| Lonza Group AG | 346.8700 |
| Date/Time | 11/08 / 19:52 |
| Chg. / Chg.(%) | - / |
| Bid | - |
| Ask | - |
| Open | 346.8700 |
| Previous Close | 346.5600 |
| High | 346.8700 |
| Low | 346.8700 |
| Volume [USD] | 693.7400 |
| Volume [Units] | 2 |
| Price fixings | 1 |
| ISIN | CH0013841017 |
| Security | LZAGF |
| Exchange | Nasdaq Other OTC |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 344.90 |  |
213,870 |
| London Inter.. | 345.74 | |
8,690 |
| Lang & Schwa.. | 312.700 | |
|
| Nasdaq Other.. | 346.8700 | 2 | |
| Cboe Europe .. | 328.30 | 47,868 | |
| Turquoise | 328.30 |  |
18,782 |
| Cboe Europe .. | 328.00 | 12,923 | |
| TradeGate | 294.000 | 298 | |
| Stuttgart | 294.000 | 135 | |
| Frankfurt | 293.9000 | 63 | |
| Düsseldorf | 291.20 | 0 | |
| München | 291.30 | 0 | |
| Berlin | 296.90 | 0 | |
| Hamburg | 291.30 | 0 | |
| gettex | 296.100 | ||
| Singapore | 79.97 | 500 | |
| EUREX | Options | ||
News
- Global Primary Cells Market Analysis, Trends, and Forecasts Report 2019
10/30/2019 / 11:17 - GlobeNewswire - Worldwide Cell Based Assay & High Content Screening Market Forecasts to 2024 - Candidate Growth, Immuno-oncology, Genomic Blizzard, Technology Convergence, The Insurance Effect
10/29/2019 / 11:55 - GlobeNewswire - Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
10/24/2019 / 15:34 - GlobeNewswire - Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
10/17/2019 / 00:17 - GlobeNewswire - Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
10/08/2019 / 08:00 - GlobeNewswire
Real-time